CBLI - Cleveland Bio files Form S-4 for Cytocom merger shares up 27%

Cleveland BioLabs (CBLI) soars 27% after-hours after filing Form S-4 with the SEC in connection with its merger agreement with Cytocom, a biopharma creating next-generation immune therapies that deliver immune homeostasis. The Registration Statement is not yet in effect.The common stock of the combined company is expected to trade on Nasdaq under the symbol "CYTO," and that the merger will potentially close during Q2. On closing of the deal, Cleveland Bio and Cytocom shareholders will own ~39% and ~61% of the combined company, respectively.Previously (Oct. 20, 2020): Cleveland BioLabs up 66% on planned merger with Cytocom

For further details see:

Cleveland Bio files Form S-4 for Cytocom merger, shares up 27%